TrimRx's Blog

A GLP-1 appeal letter wins when it does one thing well: it answers the exact reason your insurer gave for the denial, with documentation attached.

Introduction Apitegromab versus bimagrumab is a comparison between two approaches to the same goal, protecting or building muscle, that take aim at different points…

Apitegromab does not have an approved obesity indication, and its obesity timeline is early and speculative.

Apitegromab is part of a wave of drugs aiming to protect or build muscle by interfering with myostatin, the body’s natural brake on muscle growth.

Introduction AOD-9604 has an unusually reassuring side effect profile for a GH-related peptide, and the honest reason is also its biggest limitation: it was…

The anti-inflammatory peptide stack pairs KPV, BPC-157, and LL-37, three peptides that influence inflammation through separate pathways.

After major weight loss, you should get labs every year for the rest of your life, and the list is shorter and cheaper than most people fear.

Introduction Amycretin’s weight-loss results are the reason it became one of the most talked-about obesity drugs in development, and the honest version of the…

Amycretin versus semaglutide is a comparison between a promising future and a proven present, and that framing matters more than any single number.